Immunity and inflammation play critical roles in the pathogenesis of acute ischemic stroke.
Therefore, immune intervention, as a new therapeutic strategy, is worthy of exploration.
Here, investigators tested the inflammation modulator, vinpocetine, for its effect on the
outcomes of stroke. For this multi-center study, investigators recruited 60 patients with
anterior cerebral circulation occlusion and onset of stroke that had exceeded 4.5 hours but
lasted less than 48 hours. These patients, after randomly division into two groups, received
either standard management alone (controls) or standard management plus vinpocetine (30 mg
per day intravenously for 14 consecutive days, Gedeon Richter Plc., Hungary).